S4208 would amend New Jersey’s pharmacy benefit manager (PBM) law to prohibit spread pricing in pharmacy benefits management contracts. Under the bill, a PBM could not charge a carrier or purchaser one price for a prescription drug while paying the pharmacy a lower amount and keeping the difference; instead, contracts would need to use a passthrough model in which rebates, fees, alternative discounts, and other remuneration tied to drug utilization are remitted in full to the carrier, health benefits plan, or purchaser. The bill also clarifies that PBMs may still charge a defined pharmacy benefit management fee, so long as that fee reflects the bona fide value of services actually performed and is not tied to drug prices, rebates, patient cost-sharing, formulary decisions, or other specified metrics.
The bill adds new transparency and reporting requirements. PBMs would have to submit annual audited financial statements to the Department of Banking and Insurance within 120 days after the close of the fiscal year, along with quarterly unaudited statements, and the commissioner could require more frequent reporting. The department would also be required to produce an annual public report, beginning one year after enactment, summarizing PBM compensation, pricing, financial statements, and the effect of those practices on health benefits plan costs, with personal identifying information removed. The bill applies immediately to new contracts, renewals, and extensions entered into on or after enactment.
In terms of state-law impact, the bill would further amend P.L.2023, c.107 and expand New Jersey’s regulation of PBMs, carriers, and health benefits plans. It would affect contracts involving commercial carriers, the State Health Benefits Plan, the School Employees’ Health Benefits Plan, the State Medicaid program, and self-insured ERISA plans covered by the statute’s definitions. It also imposes new compliance, auditing, and disclosure obligations on PBMs and oversight duties on the Department of Banking and Insurance.
The overall sentiment reflected in the bill text is strongly reform-oriented and consumer-protective, with the stated goal of increasing transparency and limiting pricing practices that can raise prescription drug costs. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of legislative debate or formal support/opposition in the available context. The bill’s structure suggests support for greater oversight of PBM compensation and pricing, while the main policy concern it addresses is the perceived lack of transparency and potential cost inflation associated with spread pricing.
The main point of contention is likely the prohibition on spread pricing and the requirement that PBMs remit all related rebates and remuneration, since those provisions directly alter PBM business models and revenue streams. PBMs and affiliated entities may view the reporting mandates and limits on compensation as burdensome or commercially restrictive, while carriers, purchasers, pharmacies, and covered persons may favor the bill’s transparency and pass-through requirements as a way to reduce hidden costs and improve accountability.
The bill would amend New Jersey’s existing PBM statute to ban spread pricing, require passthrough of rebates and related remuneration, and impose detailed financial reporting and audit requirements on PBMs. It would affect PBM contracts with carriers, purchasers, pharmacies, and health benefits plans, including state health plans and Medicaid, while directing the Department of Banking and Insurance to oversee compliance and publish annual public reports.
The available text indicates a generally favorable, reform-minded posture toward tighter PBM regulation, transparency, and consumer cost protection. No committee discussion or vote record is provided, so there is no documented opposition or bipartisan split in the supplied materials; the bill appears framed as a response to concerns about opaque pricing and prescription drug costs.
The central controversy is the bill’s ban on spread pricing and its requirement that PBMs pass through rebates, fees, and other remuneration in full, which would significantly constrain PBM compensation practices. PBMs and potentially some carriers may object to the operational and financial impact of these restrictions and the added reporting burden, while consumer advocates, purchasers, and pharmacies are likely to support the bill as a transparency and cost-containment measure.